Commercialising A Unique Solution For Antibiotic Resistance

Helperby Therapeutics Addresses A Clear Unmet Need In Areas Of Significant Market Value

Helperby has three development candidates in clinical trials:

HY-001 (Urinary Tract Infection) - Phase I completed
HY-004 (Nasal MRSA) - Phase II
HY-007 (Consumer Antibacterial) - Market ready

View full development candidate pipeline »

We are actively seeking business development partners.

We help other companies to rescue their antibiotics from resistance

Helperby has worked with companies which are in different stages of development.

Please contact us to discuss your requirements.

News

21 Jul 2019 • Urinary Tract Infections Affect Millions. The Cures Are Faltering.

14 May 2019 • Antibiotic Combinations Could Be A Revolution In Fight Against Superbugs

14 May 2019 • Antibiotic Resistant Superbugs Creating Deadly Risks For Hip & Knee Operations

14 May 2019 • Take Over Pharma To Create New Medicines, Says Top Adviser

15 Feb 2019 • Antibiotic-Resistance-Plan-To-Fight-Urgent-Global-Threat

27 Jul 2018 • Develop New Antibiotics or Face Fines, Drug Firms Told

27 Apr 2018 • Figures reveal emergence of ‘pan-resistant’ infections

3 Apr 2018 • Scots gran has all limbs cut off after PAPER CUT leads to sepsis

Key Papers

• Novel classes of antibiotics or more of the same?

• Novel approaches to developing new antibiotics for bacterial infections

• Can We Prevent Antimicrobial Resistance by Using Antimicrobials Better?

• Antibiotic Resistance - Global Response Needed

• Antimicrobial resistance characteristics and fitness of Gram-negative fecal bacteria from volunteers treated with minocycline or amoxicillin.

• Antibiotic Resistance Breakers: Revitalize Conventional Antibiotics. In: Novel Antimicrobial Agents and Strategies.

Copyright © 2019 Helperby : All Rights Reserved